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Abstract: Transmucosal drug delivery includes the administration of drugs via various mucous
membranes, such as gastrointestinal, nasal, ocular, and vaginal mucosa. The use of nanoparticles in
transmucosal drug delivery has several advantages, including the protection of drugs against the
harsh environment of the mucosal lumens and surfaces, increased drug residence time, and enhanced
drug absorption. Due to their relatively simple synthetic methods for preparation, safety profile, and
possibilities of surface functionalisation, silica nanoparticles are highly promising for transmucosal
drug delivery. This review provides a description of silica nanoparticles and outlines the preparation
methods for various core and surface-functionalised silica nanoparticles. The relationship between
the functionalities of silica nanoparticles and their interactions with various mucous membranes
are critically analysed. Applications of silica nanoparticles in transmucosal drug delivery are
also discussed.
Keywords: silica nanoparticles; organosilica; transmucosal drug delivery; mucoadhesion;
mucosal penetration
1. Introduction
Among inorganic nanomaterials, silica nanoparticles have attracted a lot of attention in
nanomedicine. Silicon-based materials and their oxides (e.g., silica, silicon dioxide, SiO2) are appealing
as nanomaterials for medical applications because not only do they exist abundantly in nature, but they
are also biocompatible. Indeed, silica is “generally regarded as safe” and is approved by the United
States Food and Drug Administration (FDA) as an adjuvant (e.g., as an anticaking agent, defoaming
agent and emulsifier) in the food industry [1–3].
Broadly, silica nanoparticles can be classified as nonporous (solid) or mesoporous (pore size:
2–50 nm; Figure 1), both with a similar composition and an amorphous silica structure [4]. The key
distinctions are that mesoporous silica nanoparticles have a porous structure, a lower density, and
a larger effective surface area [5]. Mesoporous silica nanoparticles are considered as promising
nanocarriers for various therapeutic agents, including small molecules, macromolecules, and vaccines
which can be loaded into the nanoparticles via physical and chemical adsorption [4,6]. Nonporous silica
nanoparticles are also used to load different drugs using encapsulation and conjugation techniques [4].
Depending on the silica source, silica nanoparticles can also be categorised into inorganic nanoparticles
or organosilica nanoparticles. Inorganic silica nanoparticles are prepared from pure alkoxysilanes,
typically tetraethylorthosilane (TEOS), whilst organosilica are partly prepared from substituted
alkoxysilanes [R-Si(OR′)3] [7]. These silica nanoparticles can be prepared using relatively simple
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methods with basic laboratory equipment, and can be easily functionalised using a variety of molecules,
such as polymers and fluorescent dyes, to enhance their properties for drug delivery and tracking.
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However, to the best of our knowledge, there is currently no review discussing the application of 
functionalised silica nanoparticles specifically in transmucosal drug delivery. Considering some 
interesting studies, trends, and applications that have emerged in recent years, there is a strong need 
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Traditionally, silica nanoparticles are prepared using the Stöber method [19], in which TEOS is 
used as the silica source, water and ethanol as solvents, and ammonia as a catalyst. This method 
generally involves the hydrolysis of TEOS to form silicic acid, followed by condensation of the silicic 
acid to produce silica particles with siloxane bridges (Si-O-Si) (Figure 2). Nucleation and particle 
growth are involved in the formation of the silica nanoparticles [20-24]. Nucleation is the formation 
of solid particles (nuclei) from soluble TEOS monomers in a homogenous liquid. Particle growth is 
achieved either through the addition of TEOS monomers to the nuclei [23,24], or the aggregation of 
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Figure 1. Transmission electron microscopy images of (A) nonporous silica nanoparticles (synthesised
from SiO2 using the Stöber method). Reprinted with permission from [8]. Copyright (2011) American
Chemical Society. (B) isothiocyanate-functionalized mesoporous silica nanoparticle made of TEOS and
3-aminopropyl triethoxysilane. Reprinted from [9].
Due to the insolubility of silica and its stability in the harsh gastrointestinal environment containing
gastric acid and various proteases, solid silica nanoparticles can potentially be used to protect molecules
(e.g., proteins, DNA and RNA) that are liable to degradation in such an environment, and even control
their release [6,10]. Solid silica nanoparticles can be advantageous over biodegradable nanocarriers
(e.g., polymeric nanoparticles and liposomes) because, in the latter, the drug payload would leach out
when they come into contact with the physiological environment, resulting in premature drug release.
In most cases, this will lead to a failure of site-specific drug delivery and thus ineffective therapy [10].
Several excellent reviews have previously been published on silica nanoparticles, their synthesis,
properties, functionalisation, and various applications [11–13]. Mesoporous and nonporous silica
nanoparticles have also been extensively reviewed for some biomedical applications [4,14–18]. However,
to the best of our knowledge, there is currently no review discussing the application of functionalised
silica nanoparticles specifically in transmucosal drug delivery. Considering some interesting studies,
trends, and applications that have emerged in recent years, there is a strong need to discuss such an
application in a review.
This review provides an introduction to silica nanoparticles, a brief explanation of the common
methods of their synthesis, and highlights their potential in transmucosal drug delivery. Additionally,
some safety concerns and the in vivo biodistribution of silica nanoparticles are discussed.
2. Common Methods of Preparation of Silica Nanoparticles
Traditionally, silica nanoparticles are prepared using the Stöber method [19], in which TEOS is
used as the silica source, water and ethanol as solvents, and ammonia as a catalyst. This method
generally involves the hydrolysis of TEOS to form silicic acid, followed by condensation of the silicic
acid to produce silica particles with siloxane bridges (Si-O-Si) (Figure 2). Nucleation and particle
growth are involved in the formation of the silica nanoparticles [20–24]. Nucleation is the formation
of solid particles (nuclei) from soluble TEOS monomers in a homogenous liquid. Particle growth is
achieved either through the addition of TEOS monomers to the nuclei [23,24], or the aggregation of the
nuclei to form larger particles [20,25].
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(100 ◦C) instead of room temperature narrowed the size distribution of MPMS silica nanoparticles [36].
The hybrid organosilica nanoparticles were synthesised from a combination of MPMS and MPDMS in
the presence of sodium dodecyl sulfate as a surfactant [37]. Solid-state 13C nuclear magnetic resonance
and Raman spectroscopy revealed the presence of disulfide bonds in the structure of these hybrid
(MPMS–MPDMS) nanoparticles. Using transmission electron microscopy (TEM), it was found that
MPMS–MPDMS organosilica nanoparticles degraded in the presence of glutathione. This degradation
manifested as irregular shapes in the decomposed nanoparticles, compared to the regular spheres
observed in the absence of glutathione. This could be due to the ability of glutathione to attack
the disulfide bonds of the nanoparticles via thiol/disulfide exchange reaction which leads to the
oxidation of glutathione itself and the consumption of a portion of the reduced form of glutathione by
the nanoparticles as indicated by Ellman’s assay [37]. The glutathione-responsive degradability of
MPMS-MPDMS organosilica nanoparticles makes these nanoparticles a promising carrier for targeted
delivery of anticancer drugs due to the presence of a higher concentration of glutathione in cancer cells
compared to normal cells [37].
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resulted in the formation of silica nanoparticles. It was found that the presence of a small proportion of
APMS was necessary to produce colloidally stable nanoparticles. The molar ratio of MPMS/APMS
in the reaction mixture was directly proportional to the zeta potential but inversely proportional to
the thiol content. As these nanoparticles had positively charged surfaces (their zeta potential ranged
from 30 to 50 mV), they bound to antisense oligodeoxyribonucleotide (G3139) efficiently as a result of
electrostatic attraction between the cationic nanoparticles and the anionic therapeutic [38].
Silica nanoparticles can also be synthesised using a reverse microemulsion method where the
silica source (TEOS or TMOS) is added to a preformed water-in-oil emulsion [39]. Again, here, the size
of the nanoparticles can be tuned by the composition and the pH of the aqueous phase, changing
the type of emulsifier, water-to-emulsifier ratio, amount of TEOS, and the type of organic solvent
comprising the organic phase of the emulsion [40,41].
Irmukhametova et al. [42] have pioneered the formation of thiolated silica nanoparticles (with the
size of ~50 nm) from MPMS using DMSO as a solvent and NaOH as a basic catalyst. The mechanism
driving the formation of these nanoparticles is believed to be the hydrolysis and subsequent
condensation of the methoxysilane groups in MPMS, as well as the formation of disulfide bonds via
partial oxidation of the thiol groups in MPMS. Observation of the turbidity of the reaction mixture
during nanoparticle synthesis confirmed that air bubbling the reaction mixture is necessary to form
stable colloidal thiolated silica nanoparticles. It was hypothesised that the oxygen present in the air
could oxidise some of the thiol groups of MPMS, resulting in the formation of disulfide bridges. In the
absence of oxygen (but in the presence of N2), no significant changes in the turbidity of the reaction
mixture were observed. Control experiments performed using a water–ethanol mixture instead of
DMSO resulted in milky suspensions of large particles. This could be due to the fact that protic
solvents, such as water and ethanol, could facilitate the hydrolysis and subsequent condensation
of methoxysilane groups to ultimately result in faster nucleation and particle growth compared to
DMSO [42].
Later, Al Mahrooqi et al. [43] investigated the effects of various parameters, including catalyst
type and concentration, MPMS concentration and solvent type on the physicochemical properties of
these thiolated silica nanoparticles. From the dynamic light scattering (DLS) analysis, it was found that
the size of the nanoparticles decreased from ~290 nm to ~50 nm with increasing NaOH concentration
(0.05 M up to 0.5 M), but a further increase in the concentration of NaOH (0.5 to 0.9 M) did not
significantly change the size of the nanoparticles. Additionally, it was found that the thiol content
of the nanoparticles (measured by Ellman’s assay) increased with increasing NaOH concentration.
The use of an acidic catalyst (HCl) not only resulted in larger particles, but the particle size increased
with increasing HCl concentration (the mean particle size was 1.18, 5.30, and 10.46 µm when 0.1, 0.3
and 0.5 M HCl was used, respectively). With an increasing concentration of MPMS (but only over a
limited range of 0.13–0.40 M), a linear increase in the size of the nanoparticles was observed. However,
a lower concentration of MPMS (0.04 M) resulted in an increase in the size of the nanoparticles. Further
experiments using different organic solvents revealed that increasing the dielectric constant of the
solvents decreased the nanoparticles size wherein nanoparticles synthesised using DMSO (with a
dielectric constant of 47) had the smallest size (45 ± 3 nm) and low polydispersity index (0.181) [43].
Clearly, the ability to control the physicochemical properties of these thiolated silica nanoparticles
can have a significant impact on the behaviour (e.g., mucoadhesion and biodistribution) of these
nanoparticles in biological environments.
3. Applications of Silica Nanoparticles in Drug Delivery: Loading Capacity and Release
Silica nanoparticles are now extensively used as nanocarriers for the delivery of various drugs
having different physiochemical, pharmacokinetic and pharmacodynamic properties. Their main
applications in drug delivery include improving the dissolution rate of poorly water-soluble drugs,
controlled release, and targeted drug delivery [44–46]. Initially, MCM-41 have been used to control
the release profile of ibuprofen [47]. The loading capacity and ibuprofen release could be controlled
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using various functional groups of silica pore wall [47,48]. Generally, the same methods which are
used to load drugs into the other nanoparticles are also used for the silica nanoparticles. These include
drug loading during the synthesis of the nanoparticles and also after the nanoparticles are formed.
However, polymer-based drug delivery systems usually need the organic solvents for drug loading,
which cause some toxicological issues [49]. The mechanism of the drug release from silica nanoparticles
mainly depends on the diffusion of the drug molecules from the pores of the nanoparticles. However,
in polymer-based drug delivery systems the release depends either on the hydrolysis-induced erosion
of the polymer or on the swelling of polymeric matrix which is usually occurred upon dispersion
of the systems in the biological environments [49]. This will lead to premature drug release and
the lack of control over the drug release in the target sites which causes ineffective drug therapy
and unwanted systemic side effects. Stimuli-responsive silica nanoparticles release the loaded drug
upon both endogenous (e.g., pH, enzyme, redox, and glucose) and exogenous (light, temperature,
ultrasound, electric and magnetic fields) stimulation [50]. The ordered porous structure of mesoporous
silica nanoparticles allows easy loading of various drugs into these nanoparticles and homogenous
distribution of the drugs in the nanoparticles. The size, shape and the surface properties of the pores
affect the drug loading capacity, the nanoparticles-drug interactions, the drug release properties and
finally the therapeutic activities [5]. Thus, drugs with molecular size smaller than nanoparticles
pore size can be loaded into the nanoparticles. For loading proteins and larger macromolecules,
nanoparticles with larger pore size are required [5]. The surface properties also determine the nature
of the nanoparticles-drug interactions and this can be tuned with the surface functionalisation which
includes the introduction of various functional groups at the surface of the nanoparticles leading
to the desired surface charge, surface chemistry and the hydrophilic-lipophilic character of the
nanoparticles [5]. The nature of the nanoparticles-drug interactions has a significant role in determining
the loading capacity and the drug release profile. For instance, Wani et al. [51] demonstrated that
methotrexate loading capacity of thiol-functionalised mesoporous silica nanoparticles was significantly
higher (18%w/w) than both mixed thiol-amine (6%w/w) and amine (1%w/w) functionalised counterparts.
Wani et al. [51] also observed a strong pH dependence of methotrexate release from thiol-functionalised
mesoporous silica nanoparticles with a rapid release in acidic pH and a very slow release in neutral
pH. In contrast, they observed almost similar methotrexate release profile from both amine and
mixed thiol-amine functionalised silica nanoparticles which was rapid and pH-independent. Strong
electrostatic interactions between methotrexate and negatively charged thiol-functionalised silica
nanoparticles not only increased the drug loading capacity but also significantly decreased the rate of
drug release. Decreasing the ionization of the silica in acidic pH weakens the interactions and facilitates
rapid drug release [51]. Moreover, Datt et al. [52] showed that amine functionalized MCM-41 provided
a slow drug release due to the strong interaction between the amino groups of the nanoparticles and the
carboxyl groups of aspirin. However, non-functionalised MCM-41 showed a rapid aspirin release [52].
Many other publications have reported the feasibility of plain and functionalised silica nanoparticles
in controlled drug delivery [53–55].
4. Transmucosal Drug Delivery
Transmucosal drug delivery refers to the administration of therapeutic agents via mucosal
membranes. The established routes of transmucosal administration include the oral cavity (buccal,
gingival and sublingual) [56], esophagus [57], gastrointestinal tract (GIT) [58], nose [59], eyes [60],
rectum [61], vagina [62], and urinary bladder [63]. Transmucosal drug delivery has several advantages
including the ease of administration, non-invasive nature, and improved patient compliance. However,
there are some obstacles in transmucosal drug delivery, including luminal (pH and enzymes), mucus
and epithelial barriers. The strategies of mucoadhesion, mucus-penetration and nanoscale technologies
have been used to overcome these barriers [64–68]. Mucoadhesion refers to the phenomenon whereby
synthetic or natural materials adhere to mucous membranes [69,70]. The application of mucoadhesive
materials first appeared in dentistry in 1947 when Scrivener and Schantz mixed tragacanth gum with
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a dental adhesive to deliver penicillin to the oral mucosa [68]. This later led to the development of
Orabase ® [68] which is commonly used for the treatment of oral ulcer. Later the research of Nagai
with co-workers in the 1980s reported the potential of mucoadhesion in drug delivery where polymers
such as hydroxypropyl cellulose and Carbopol 934 were used in the design of various dosage forms.
These include vaginal discs for delivering bleomycin (an anticancer drug) to the mucosal surfaces of
the human cervical canal, discs containing insulin and tablets of triamcinolone acetonide (marketed as
Aftach, used for the treatment of aphthous stomatitis), both for administration to the oral mucosa, as
well as a powder formulation of insulin for nasal administration [71,72]. Since then, various classes of
polymers have been used in the design of mucoadhesive drug delivery systems.
Thiomers are a class of mucoadhesive materials which can be synthesised through the immobilisation
of thiol groups on various materials. Some examples of thiomers include thiolated-polycarbophil [73],
chitosan [74], pectin [75,76], graphene oxide [77], polyvinylpyrrolidone [78], and hyaluronic acid [79].
Their mucoadhesive properties can be due to their ability to form disulfide bonds with cysteine-rich domains
of mucus glycoproteins via thiol/disulfide exchange reactions or oxidation of their thiol groups. In situ
cross-linking can be another possible mechanism for the mucoadhesion of thiomers [80].Various dosage forms
have been prepared using these thiomers with enhanced mucoadhesive properties. These include micro-and
nanoparticles, matrix tablets and eye drops [80]. Several other materials with enhanced mucoadhesive
properties including polymers bearing catechol, boronate, acrylate, methacrylate, and maleimide functional
groups are developed and were recently discussed by Brannigan and Khutoryanskiy [81].
5. Factors Influencing Mucosal Drug Delivery
Researchers are currently investigating two main types of mucosal drug delivery systems
which are mucoadhesive and mucus-penetrating formulations. The mucoadhesive formulations
are able to adhere to the the mucus layer of the mucosal membranes. To date, six theories explain
mechanisms of mucoadhesion and these include electronic, adsorption, wetting, diffusion, fracture
and mechanical theory [68]. Mucoadhesive formulations enhance the drug retention time at the site of
absorption/action, which can lead to the enhanced drug bioavailability. Mucoadhesive formulations
are typically prepared using hydrophilic polymers having ionic and/or non-ionic functional groups
with the ability of hydrogen bond formation with the mucus components. They generally show
strong physical and chemical interactions with the mucin macromolecules, hardly diffuse through
mucus layer, and are trapped in the mucus gel [68]. In contrast, mucus-penetrating formulations
do not contain materials with mucoadhesive properties and are non-ionic or net-neutral hydrophilic
polymers with stealth properties. They usually do not interact with the components of the mucus
(mucus-inert) and can reach the underlying epithelial tissues and deliver the loaded drugs in the
desired tissue [82]. Consequently, mucus-penetrating formulations have a short mucosal retention time.
Alternatively, the mucus-penetrating formulations can be designed using the concepts of zeta-potential
changing [83] and mucolysis [84]. The dosage form-mucin interactions are considered as influencing
factors in mucosal drug delivery as they determine whether the formulation is mucoadhesive or
mucus-penetrating. The other factors which affect the efficiency of mucosal drug delivery are the
physicochemical characteristics of the dosage form and the drug (e.g., particle size, shape and
zeta potential) and the physiological conditions, e.g., pH, presence of enzymes, the type of mucosa,
the mucus thickness and the mucus turnover rate. Short-chain PEG is a typical example of the
polymers used in the design of various mucus-penetrating formulations including nanoparticles [85],
liposomes, and micelles [86], but some other materials have also been explored which are discussed
by Khutoryanskiy [82]. Both mucoadhesive and mucus-penetrating nanoparticles are desirable in
transmucosal drug delivery as each one has its own features and advantages. There is also an emerging
trend in formulating nanomedicines using combination of mucoadhesive and mucus-penetrating
nanoparticles for the efficient transmucosal drug delivery [87–89].
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6. Applications of Silica Nanoparticles in Transmucosal Drug Delivery
Silica nanoparticles have a range of potential applications including drug delivery (mucosal
and controlled delivery) [51,65,90–92], diagnostics [93], and tissue engineering (mainly for bone
regeneration) [94,95]. In this section, we will discuss the applications of silica nanoparticles in
transmucosal drug delivery. The thiolated silica nanoparticles developed by the Khutoryanskiy
group have abundant thiol groups which can be prepared in a single-step process (unlike the
nanoparticles based on thiomers which require two steps of synthesising the polymers and then
elaborating the nanoparticles from the thiomers thus synthesised). These thiolated silica nanoparticles
can be functionalised with polyethylene glycol (PEG) [42], poly-2-ethyl-2-oxazoline (POZ) [96],
poly-2-methyl-2-oxazoline, and poly-2-n-propyl-2-oxazoline [97], and hydroxyethylcellulose [98].
Upon functionalisation a significant number of the free thiol groups will be masked by the
polymers and therefore would not be available for chemical reactions. Thiolated silica nanoparticles
exhibited mucoadhesive properties in vitro on bovine cornea [42], porcine bladder mucosa [99] and
rat intestinal mucosa [90]. Their mucoadhesiveness was reduced upon PEGylation (PEGylated
silica nanoparticles) [42,99] and POZylation (POZylated silica nanoparticles) [90]. However,
these modifications enhanced their diffusion in porcine gastric mucin dispersions and penetration into
the porcine gastric mucosa, as measured by nanoparticle tracking analysis and fluorescence microscopy,
respectively (Figure 4) [96]. As shown in Figure 4 the diffusion coefficient of PEGylated and POZylated
silica nanoparticles is greater than thiolated silica nanoparticles. Also, PEGylated and POZylated silica
nanoparticles moved further into the gastric mucosa compared to the thiolated counterpart (Figure 4).
Mun et al. [100] showed that neither thiolated nor PEGylated (with 750 and 5000 Da PEG) silica
nanoparticles penetrated the intact bovine cornea. They also revealed that thiolated silica nanoparticles
did not penetrate the de-epithelialised cornea, which could be due to the interactions of their thiol
groups with the cysteine domains of the corneal stroma. Also, PEGylated (with 750 Da PEG) silica
nanoparticles did not penetrate the de-epithelialised cornea as they had some remaining thiol groups
available for binding with the cysteine domains of the stroma. However, PEGylated (with 5000 Da PEG)
silica nanoparticles penetrated the de-epithelialised cornea, which could be due to better coverage
of silica particles with a stealth layer of larger molecular weight PEG (compared to PEGylated
nanoparticles with 750 Da PEG), decreasing the nanoparticles–cysteine interactions.Pharmaceutics 2020, 12, x FOR PEER REVIEW 9 of 28 
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Figure 4. (A) Diffusion coefficients of thiolated, PEGylated and POZylated silica nanoparticles in 1%
w/v porcine gastric mucin suspension determined by nanoparticle tracking analysis at 25 and 37 ◦C;
Data show the mean ± standard deviation, where n = 9. (B) Penetration of thiolated, PEGylated
and POZylated silica nanoparticles into porcine gastric mucosa. The values represent the means
of 3 repeats ± standard deviation; all values were subtracted from values obtained for the blanks.
*: p < 0.05, **: p < 0.01 and ***: p < 0.005. Reproduced from [96] with permission from the Royal Society
of Chemistry.
Mansfield et al. [97] also studied the effect of thiolated silica functionalisation with thre
different kDa poly(2-oxazolines): poly-2-methyl-2-oxazoline, poly-2-ethyl-2-oxazoline, and
poly-2-n-propyl-2-oxazoline on their diffusion i mucin dispersions and through freshly excised
porcine gastric mucosa. They established that alkyl chain variation could substantially affect the
ability of these nanoparticles to diffuse thr ugh muco al barriers. Nanoparticles functionalised
with poly-2-methyl-2-oxazoline and poly-2-ethyl-2-o azoline exhibited mucus-penetrating properti s,
w re s the nanomaterial decorated with more hydrophobic poly-2-n-propyl-2- xazoline did not show
any significa t incr ase in penetration compared to thiolated silica.
Zhang et al. [101] synthesised β-cyclodextrin modified mesoporous silica nanoparticles with
thre different surface functionalities, namely hydroxyl, amino, and thiol groups. These nanoparticles
were referre t as MSNPs-CD-OH, MSNPs-CD-NH2, and MSNPs-CD-(NH2)-SH, respectively.
They investigated the mucoadhesive properties of these nanoparticles through particle-mucin
interactions by measuring the size of the mixture of mucin suspension and the nanoparticles
suspension using DLS (i.e., an increase in the size indicated the presence of mucoadhesive interactions).
This was also supported by confocal microscopy of porcine bladder mucosa exposed to fluorescein
isothiocyanate-labelled nanoparticles, followed by washing with artificial urine. They found that
thiol-functionalised silica nanoparticles had superior mucoadhesiveness compared to both amino-
and hydroxyl-functionalised counterparts. This was evident from the greater change in the size of
the thiol-functionalised silica nanoparticles compared to the amino- and hydroxyl-functionalised
nanoparticles upon mixing with a mucin suspension. The size of hydroxyl-functionalised nanoparticles
did not change upon mixing with different concentrations of a mucin suspension. However, a significant
increase in the size of amino- and thiol-functionalised nanoparticles was observed (Figure 5). Also,
the mucoadhesion study showed a stronger fluorescence signal (only images without quantitative
analysis are provided in their publication) from thiol-functionalised silica nanoparticles compared to
amino- and hydroxyl-functionalised counterparts (Figure 6). Additionally, the thiol-functionalised
silica nanoparticles provided a sustained doxorubicin release, which was slower at the pH of artificial
urine (6.1) compared to the pH of phosphate buffer solution (7.4) (~13% and 63% cumulative release
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after 48 h, respectively) [101]. The greater release from the thiol-functionalised silica nanoparticles
may be due to the protonation of the amino groups of the β-cyclodextrin leading to the formation of
positively charged rings around the mesopores of the nanoparticles. As doxorubicin is also positively
charged, electrostatic repulsion will be present, which increases the size of the mesopores of the
nanoparticles and facilitates the drug release [101].Pharmaceutics 2020, 12, x FOR PEER REVIEW 11 of 28 
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Figure 5. LS size distribution of (a) MSNPs-CD-OH (MS1), (b) MSNPs-CD-NH2 (MS2) and
(c) MSNPs-CD-(NH2)-SH (MS3) after mixing with different concentrations of ucin dispersed in acetate
buffer solution (p 4.5) for 30 min. (d) Effect of mucin concentration on ucin-particle interactions.
Reprinted with permission from Zhang et al. [101]. Copyright (2014) American Chemical Society.
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Several studies have demonstrated that silicon nanoparticles that were uncoated, undecylenic
acid-modified, thermally hydrocarbonised and porous interacted weakly with Caco-2/HT29-MTX
(mono- and co-culture) cells, possibly due to the negatively charged surfaces of the nanoparticles.
However, this interaction was enhanced when the silicon nanoparticles were coated with chitosan,
through either physical adsorption or chemical conjugation, due to the adhesion of chitosan to the
mucus secreted by HT29-MTX cells [102,103]. Shrestha et al. [104] modified such silicon nanoparticles
with chitosan (to form CSUn nanoparticles). The nanoparticles were further modified with either
cysteine or a cell penetrating peptide (CPP) to generate cysteine-functionalised (CYS-CSUn) or
CPP-functionalised (CPP-CSUn) nanoparticles, respectively. They showed that both CYS-CSUn and
CPP-CSUn nanoparticles enhanced the intestinal permeation of insulin through a triple co-culture of
Caco-2, HT29-MTX and Raji B cells in a monolayer. In the case of CYS-CSUn nanoparticles, this was
due to the presence of thiol groups in the structure of the nanoparticles, which form disulfide bonds
with cysteine-rich domains of mucus glycoproteins. However, in the case of CPP-CSUn nanoparticles,
the cell-penetrating ability of CPP was the major reason for the enhanced insulin permeation through
the cells. This was confirmed by studying the interactions between the nanoparticles and the intestinal
cells using flow cytometry, TEM, and confocal microscopy. It was found that both CYS-CSUn and
CPP-CSUn nanoparticles showed stronger interactions with the surface of the intestinal cells compared
to unmodified nanoparticles (Figure 7). Indeed, CPP-CSUn nanoparticles were internalised by the
intestinal cells (Figure 7B,C). On the other hand, only CYS-CSUn nanoparticles enhanced the oral
bioavailability of insulin in a type 1 diabetic rat model. The authors linked this to the possible
degradation of the peptide layer of CPP-CSUn nanoparticles by luminal enzymes in the rat GIT, or the
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different nature of the mucus barrier of the in vivo model compared to the in vitro cell model [104].
The surface functionalisation is an interesting approach commonly used to facilitate the cellular
internalisation of the silica nanoparticles and enhance their delivery efficiency [105–108].
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Sarparanta et al. [109] reported that porous silicon nanoparticles which had been
hydrophobin-functionalised, 18F-radiolabelled and thermally hydrocarbonised (HFBII-18F-THCPSi)
showed stronger mucoadhesion in an in vitro model of human adenocarcinoma cells compared to
non-functionalised 18F-THCPSi. This could be due to the electrostatic and hydrophobic interactions
bet een specific a ino acid residues of hydrophobin and the ucus co ponents of the cells.
dditionally, the authors suggested the formation of disulfide bonds between the cysteine residue
of hydrophobin and the thiol groups of mucus glycoprotein. The in vivo study in rats using
acroautoradiography sho ed that FBII-18F-T PSi nanoparticles ere retained in the glandular
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part of the stomach for up to 3 h, due to their adhesion to the loosely bound mucus layer, followed by
their transit into the small intestine. From the radioactivity measurements (Figure 8), it was concluded
that the amount of HFBII-18F-THCPSi nanoparticles in the rat’s stomach was greater than the amount of
the non-functionalised 18F-THCPSi nanoparticles. This indicated that HFBII-18F-THCPSi nanoparticles
had a longer gastric emptying time than the non-functionalised 18F-THCPSi nanoparticles (Figure 8).
Pharmaceutics 2020, 12, x FOR PEER REVIEW 14 of 28 
 
the amount of the non-functionalised 18F-THCPSi nanoparticles. This indicated that HFBII-18F-
THCPSi nanoparticles had a longer gastric emptying time than the non-functionalised 18F-THCPSi 
nanoparticles (Figure 8). 
 
Figure 8. Comparison of gastric emptying time of HFBII-18F-THCPSi and non-functionalised18F-
THCPSi nanoparticles in rats. ID% is the percentage of injected dose, which was calculated from the 
radioactivity of the gastric tissues. Data represent mean ± standard deviation (n = 3 per time point), *: 
p < 0.05. Reprinted from Sarparanta et al. [109] with permission of Elsevier. 
The organ-specific affinity of functionalised silica nanoparticles has also been demonstrated by 
other researchers. For example, in an in vivo study in mice, Desai et al. [110] showed that 
polyethylene imine (PEI)-functionalised silica nanoparticles had a greater affinity for the small 
intestine, whereas combined PEG-PEI-functionalised silica nanoparticles had a greater affinity for the 
colon. Such types of nanoparticles have potential applications in the design of targeted drug delivery 
systems for drugs like antibiotics and anticancer agents that target the GIT. 
The effect of hydrophilic polymers on the interaction of silica nanoparticles with mucin was also 
investigated by other researchers. Andreani et al. [111] revealed that both alginate- and chitosan-
coated silica nanoparticles interacted strongly with mucin, as evident from the reduction in their zeta 
potential upon dispersion in a mucin solution. These results showed that alginate- and chitosan-
coated silica nanoparticles are mucoadhesive. In contrast, both non-coated and PEG-coated 
nanoparticles showed a weak interaction. This may indicate the ability of non-coated and PEG-coated 
silica nanoparticles to diffuse into the mucus network, i.e., they are non-mucoadhesive and therefore 
not trapped in the mucus gel. 
Liu et al. [112] studied mesoporous silica nanoparticles as a dual-drug loaded carrier for a 
hydrophobic (indomethacin) and a hydrophilic (human peptide, PYY3-36) compound. They found that 
the presence of PYY3-36 in the indomethacin/PYY3-36-loaded silica nanoparticles increased the 
permeation of both indomethacin and PYY3-36 through co-cultured Caco-2/HT29 cell monolayers. 
They related this to the presence of mucus secreted by the HT29 cells, leading to interactions between 
cell-silica nanoparticles that resulted in a high local drug concentration close to the cellular monolayers. 
Several other studies have demonstrated the potential of silica nanoparticles in transmucosal 
drug delivery. Table 1 illustrates the use of silica nanoparticles for the delivery of various drugs with 
their routes of administration, the method of evaluation of mucoadhesion/mucus penetration, surface 
chemistries, and advantages. 
Figure 8. Comparison of gastric emptying time of HFBII-18F-THCPSi and non-functionalised18F-THCPSi
nanoparticles in rats. ID% is the percentage of injected dose, which was calculated from the radioactivity of
the gastric tissues. Data represent mean ± standard deviation (n = 3 per time point), *: p < 0.05. Reprinted
from Sarparanta et al. [109] with permission of Elsevier.
The organ-specific affinity of functionalised silica nanoparticles has also been demonstrated by
other researchers. For example, in an in vivo study in mice, Desai et al. [110] showed that polyethylene
imine (PEI)-functionalised silica nanoparticles had a greater affinity for the small intestine, whereas
combined PEG-PEI-functionalised silica nanoparticles had a greater affinity for the colon. Such types
of nanoparticles have potential applications in the design of targeted drug delivery systems for drugs
like antibiotics and anticancer agents that target the GIT.
The effect of hydrophilic polymers on the interaction of silica nanoparticles with mucin was also
investigated by other researchers. Andreani et al. [111] revealed that both alginate- and chitosan-coated
silica nanoparticles interacted strongly with mucin, as evident from the reduction in their zeta potential
upon dispersion in a mucin solution. These results showed that alginate- and chitosan-coated silica
nanoparticles are mucoadhesive. In contrast, both non-coated and PEG-coated nanoparticles showed
a weak interaction. This may indicate the ability of non-coated and PEG-coated silica nanoparticles
to diffuse into the mucus network, i.e., they are non-mucoadhesive and therefore not trapped in the
mucus gel.
Liu et al. [112] studied mesoporous silica nanoparticles as a dual-drug loaded carrier for a
hydrophobic (indomethacin) and a hydrophilic (human peptide, PYY3-36) compound. They found
that the presence of PYY3-36 in the indomethacin/PYY3-36-loaded silica nanoparticles increased the
permeation of both indomethacin and PYY3-36 through co-cultured Caco-2/HT29 cell monolayers.
They related this to the presence of mucus secreted by the HT29 cells, leading to interactions between
cell-silica nanoparticles that resulted in a high local drug concentration close to the cellular monolayers.
Several other studies have demonstrated the potential of silica nanoparticles in transmucosal
drug delivery. Table 1 illustrates the use of silica nanoparticles for the delivery of various drugs with
their routes of administration, the method of evaluation of mucoadhesion/mucus penetration, surface
chemistries, and advantages.
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Table 1. Some examples of transmucosal drug delivery using silica nanoparticles in the literature.
Drugs Uses Routes ofAdministration
Models for Mucoadhesion
and Therapeutic Evaluation SURFACE Chemistries Advantages References
5-amino
salicylic acid
Inflammatory
bowel disease Oral In vivo using mice Coated with chitosan
Delayed drug release and targeted delivery to
the inflamed tissues [113]
Glucagon like
peptide-1
Type 2 diabetes
mellitus Oral In vitro using intestinal cells Coated with chitosan
Chitosan coated silica nanoparticles provided
high drug loading capacity, sustained drug
release and enhanced drug permeation
[102]
Curcumin Neurodegenerativediseases Nasal
In vitro using olfactory
neuroblastoma cells No coating
Targeting the brain,
better chemical stability of the loaded drug [114]
Doxorubicin Bladder Cancer Intravesical In vitro porcinebladder mucosa Poly(amidoamine) dendrimers
Controlling the level of surface layer though a
layer-by-layer grafting method,
Enhanced retention in bladder mucosa,
Sustained drug release which was triggered in
acidic environment
[115]
Paclitaxel (as a
model drug) Cancer Oral
Incubating particles in mucin
suspension,
Caco-2 cells,
In vivo studies in rats
Quantum dots doped hollow silica
nanoparticles were first coated with
cationic cell-penetrating peptides
and then with a mucus-inert
hydrophilic succinylated casein layer
Protects the drug from gastric acid,
Degrades and then releases the drug in small
intestine,
Enhanced mucus-penetration,
Strong interaction with epithelial membranes
and a 5-fold increase in cellular uptake,
Enhanced absolute bioavailability and in vivo
antitumor activities
[116]
Lopinavir (as
a model drug) AIDS Oral
Caco-2/HT29 cells, Everted
gut sac method, In vivo
bio-distribution studies and
pharmacokinetic
studies in rats
The core silica nanoparticles were
coated with a middle layer of a
cell-penetrating peptide and an
outer layer of a thiolated polymer
Enhanced mucoadhesion and absorption
through epithelial cells simultaneously,
Enhanced oral bioavailability
[117]
Ovalbumin (as
a model
antigen)
Vaccination Oral Mucin binding assay
3-aminopropyltriethoxysilane,
poly(methyl methacrylate) (PMMA),
PEG, chitosan
PMMA, PEG and chitosan modified
nanoparticles provided sustained drug release,
PEG and chitosan modified nanoparticles
showed high encapsulation efficiency,
Remained intact in simulated gastric and
intestinal fluids,
Showed enhanced mucoadhesion
[118]
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7. Safety Considerations and Biodistribution of Silica Nanoparticles
The safety and biodistribution of silica nanoparticles are controversial and have been found to be
highly dependent on the size, shape, surface properties, cell type, animal species, dose and the method
of administration. Using the everted gut sac method, Yoshida et al. [119] demonstrated that silica
nanoparticles of various sizes (70, 300, and 1000 nm) and surface functionalities (carboxyl or amino
groups) were absorbed by the rat small intestine. However, they observed no abnormalities in the
mice after a 28-day oral exposure to these nanoparticles, as indicated by histopathology examination
of the liver, kidney, brain, lung, spleen, heart, stomach and intestine and haematological analysis.
Using TEM, Yoshida et al. [120] found that following nasal administration of silica nanoparticles in
mice (20 µL, at 500 µg/mouse daily for 7 days), the particles of 30, 70, and 100 nm were absorbed
by the nasal mucosa and detected in the nasal cavity, lung and liver. On the other hand, 1000 nm
particles were detected in the nasal cavity and lung, whereas 300 nm particles were only detected in the
lung. Neither the 300 nm nor the 1000 nm particles were detected in the liver. Yoshida et al. [120] did
not provide any explanation for the difference observed in the biodistribution of these nanoparticles,
but suggested that TEM was only a qualitative method and thus no quantitative data could be obtained.
They also hypothesised that the larger nanoparticles (300 nm and 1000 nm) degraded in the biological
environment into smaller nanoparticles [120], which could explain why these nanoparticles were not
detected in the liver. However, they did not show any experimental data to support the fact that these
nanoparticles degrade in the biological environments as the biodegradability of silica nanoparticles is
controversial and it mainly depends on the type of the nanoparticles [121–123]. In terms of toxicity,
only the 30 nm and 70 nm nanoparticles prolonged the bleeding time of mice compared to the control.
No adverse biological effects were observed with the other nanoparticles [120].
In rats, subcutaneous injection of mesoporous silica particles (150–4000 nm) produced no apparent
toxicity. However, intravenous and intraperitoneal injections in mice led to the death of the animals,
possibly due to pulmonary thrombosis [124]. Oral and ocular administration of nonporous silica
nanoparticles to rats for 12 weeks was found to be safe [125].
Li et al. [126] observed possible renal impairment with sphere-like mesoporous silica nanoparticles
but not with rod-like mesoporous silica nanoparticles when orally administered to mice. They also
reported that the silica nanorods mainly accumulated in the liver and spleen of the mice, whereas
the silica nanospheres were mainly found in the spleen. Some other investigators have revealed the
impact of silica nanoparticle shape on their toxicity, biodistribution, and biocompatibility [8,127,128].
Bukara et al. [129] found that ordered mesoporous silica nanoparticles are well tolerated by human
volunteers and the nanoparticles improved the oral bioavailability of fenofibrate.
It can be concluded that the toxicity of the silica nanoparticles mainly depends on the chemical
composition, the size, the shape and the routes of administration of the nanoparticles [3,128]. Different
mucosal surfaces show different barrier properties to various silica nanoparticles. In other words,
silica nanoparticles do not penetrate mucosal tissues with different pore sizes of the mucus gel, mucus
thickness, and pH to the same extent.
8. Potential for Future Research
Since the pioneering studies by Nagai et al. [71,72], hydrophilic polymers have been traditionally
used in the design of mucoadhesive dosage forms for transmucosal drug delivery. Their mucoadhesive
properties were related to the ability of functional groups to interact with mucins via electrostatic
interactions and hydrogen bonding as well as to the ability of polymeric macromolecules to diffuse into
the mucus gel and form interpenetrating layers [130,131]. In recent years, a significant progress has been
achieved in functionalisation of various polymers to make them more mucoadhesive. Several synthetic
strategies have emerged including functionalisation of polymers with thiol-, catechol-, boronate-,
acrylate-, methacrylate-, maleimide-, and N-hydroxy(sulfo)succinimide ester-groups [81].
Silica nanoparticles simply composed of silicon dioxide do not exhibit substantial mucoadhesive
properties. However, due to the numerous possibilities for their surface functionalisation it is possible
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to make them mucoadhesive. Some studies demonstrating the mucoadhesive properties of silica
nanoparticles through the chemical functionalisation of their surfaces already emerged, which include
thiolation and decoration with amino-groups. More research is expected in this area considering the
substantial expansion in the chemistries favouring mucoadhesion that have emerged in recent years
in the studies of mucoadhesive polymers [81]. Advances in this area are also expected not only with
silica, but also with other inorganic and hybrid colloids, such as metals (e.g., gold and silver) and other
inorganic oxide nanoparticles (e.g., titanium dioxide). Some progress in surface-functionalised gold
nanoparticles has recently been reported [132].
Another area for the potential development and application of silica nanoparticles in
transmucosal drug delivery arises from a recently emergent interest in mucus-penetrating particles.
Hanes et al. [133–135] demonstrated the excellent potential of PEGylated nanoparticles of polymeric
nature for transmucosal drug delivery. Some other studies also reported the potential of PEGylated
materials in the formulation of mucus-penetrating nanoparticles [136–139]. Some non-ionic polymers
other than polyethyleneglycol were also reported to exhibit mucus-penetrating properties [82].
Our research group has recently demonstrated the possibility of making silica nanoparticles more
mucus-and tissue-penetrating via their PEGylation and POZylation [96,97,99,100]. Due to the relative
ease of silica surface functionalisation with polymers, some further research is expected in the
development of novel mucus-penetrating silica-based particles.
Further studies on the safety in human, reproducibility, stability and scalability of the silica
nanoparticles are expected. Numerous studies reported the toxicity profiles of silica nanoparticles
in vitro cells or animal models [140–145]. However, to date, only one study confirmed that silica
nanoparticles are safe in healthy humans [129]. Silica nanoparticles are usually prepared at the small
scale in research laboratories with the proper control of various important formulation parameters,
including the pH, temperature, oxygen level, etc., which usually results in a reproducible control of the
nanoparticles size, polydispersity index, and shapes. However, the preparation of silica nanoparticles
on industrial scale is likely to be a challenging task due to the difficulties in controlling the formulation
parameters. Advances in characterisation techniques can potentially allow better control on the size
and the long-term stability of the silica nanoparticles which can improve the reproducibility of the
nanoparticles. Studies on the aforementioned areas may lead to the translation of these promising
drug delivery systems from the bench to the clinic.
9. Conclusions
Silica nanoparticles are promising drug nanocarriers for transmucosal drug delivery, due to their
relatively simple methods of preparation, control over particle size and shape, high drug loading,
and controlled drug delivery. Different silica nanoparticles could be synthesised bearing various
functional groups. Some surface functional groups (for example, amino or thiol groups) could make the
nanoparticles more mucoadhesive. These groups could also be used to functionalise the nanoparticle
with polymers. PEGylation and POZylation of silica nanoparticles could make them mucus-penetrating.
Although silica nanoparticles have generally been found to be relatively safe, a few studies have
raised some safety concerns. These suggest further pre-clinical investigations to explore their potential
applications in transmucosal drug delivery.
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